Selected Grants
Otsuka HF Ph2 POC
Clinical TrialPrincipal Investigator · Awarded by Otsuka Pharmaceutical Development & Commercialization, Inc. · 2024 - 2027PARACOR-19
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2021 - 2026Identifying barriers to and optiMizing in-hosPitaL usE of evidenced-based Medical thErapies for patieNTs with Cardio-Renal-Metabolic Disease (IMPLEMENT-CRM)
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2026Goals-HF
Clinical TrialPrincipal Investigator · Awarded by Tricog Health Inc. · 2023 - 2025Use and Effectiveness of Outpatient Intravenous Diuretic Therapy as Treatment for Worsening Heart Failure
ResearchPrincipal Investigator · Awarded by American Heart Association · 2022 - 2025TRANSFORM-HF DCC
ResearchCo Investigator · Awarded by National Institutes of Health · 2017 - 2024Comparison of Dyspnea Measurement Instruments in Acute Heart Failure
Clinical TrialPrincipal Investigator · Awarded by Heart Failure Society of America · 2017 - 2019External Relationships
- AstraZeneca
- Bayer
- Boehringer Ingelheim/Lilly alliance
- Boehringer Ingleheim
- Bristol-Myers Squibb
- CSL Vifor
- Corteria Pharmaceuticals
- Cytokinetics, Inc.
- Lexicon Pharmaceuticals, Inc.
- Merck Sharpe & Dohme (Merck & Co, USA)
- Novartis
- Novo Nordisk
- Otsuka Pharmaceuticals
- Pfizer Inc.
- PharmaIN
- Roche Diagnostics
- Roivant
- Sanofi
- Tricog Health
- Urovant Pharmaceuticals
- scPharma
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.